HCW Biologics (NASDAQ: HCWB) — Perfil da empresa, notícias e dados financeiros
HCW Biologics is a clinical-stage company developing immunotherapies to combat chronic inflammation associated with aging and diseases.
HCWB HCW Biologics
Perfil da empresa
HCW Biologics
HCW Biologics (NASDAQ:HCWB) is a clinical-stage company developing immunotherapies to combat chronic, low-grade inflammation, a hallmark of aging and many diseases. Their focus is on disrupting this inflammatory process to improve healthspan, essentially the length of healthy life. They're currently in the development phase of novel immunotherapeutic drugs and haven't launched any commercial products yet. HCW Biologics is a small-cap company with a market capitalization around $41 million.
Resumo
Public USParticipação acionária
2018Ano de fundação
45Funcionários
Miramar, United StatesSede
Carregando mapa...
Presença global
Operações
Todos os locais
Miramar, US
Produtos e/ou serviços de HCW Biologics
- Immunotherapy Research & Development: HCW Biologics researches and develops novel immunotherapy drugs targeting chronic, low-grade inflammation.
- Pre-Clinical and Clinical Trials: They conduct pre-clinical studies in labs and potentially clinical trials to test the safety and efficacy of their drug candidates.
- Collaboration with Research Institutions: HCW Biologics might collaborate with other research institutions to advance their discoveries.
- Data Analysis & Reporting: They analyze data from studies and trials, reporting findings to regulators and the scientific community.
- Investor Relations & Communication: HCW Biologics communicates with investors regarding their progress and developments.
- Intellectual Property Management: The company likely manages patents and other intellectual property related to their discoveries.
equipe executiva do HCW Biologics
- Hing C. WongFounder, CEO, Director & Secretary
- Rebecca ByamChief Financial Officer
- Peter RhodeChief Scientific Officer & VP of Clinical Operations
- Nicole ValdiviesoVice President of Legal Affairs
- Lee D. FlowersSenior Vice President of Business Development
Últimas notícias sobre a HCW Biologics
Principais indicadores financeiros
Resultados divulgados pela HCW Biologics, em USD.
- Cap. de mercado
- 2,5 mi
- Receita (TTM)
- 6,7 mi
- P/L
- —
- LPA (diluído, TTM)
- -19.8
- Dividend yield
- —
- Margem de lucro
- -83.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 54,2 mil | -11,3 mi | -8 mi | |
| 2,6 mi | -29,5 mi | -30 mi | |
| 2,8 mi | -25,7 mi | -25 mi | |
| 6,7 mi | -15,1 mi | -14,9 mi |